CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML.

Cancers (Basel) · 2022 · PMC9221356 · PMID 35740508

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Although not significant, there was a favorable trend suggesting a longer OS also in patients with unfavorable cytogenetic characteristics and in those who harbored a FLT3 mutation treated with CPX-351.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.